CMS launching payment model to boost access to GLP-1s
The Trump administration has unveiled yet another new payment model, this one focused on the cost of GLP-1 therapies. The...
Omada touts strong results of GLP-1 companion program
Despite the hype about weight loss drugs known as GLP-1s, serious questions have remained about their efficacy when patients wean...
KFF analysis finds a median ACA premium hike of 18% for 2026
Health insurers are seeking steep premium increases on the Affordable Care Act’s exchanges next year, according to a new analysis...
Cost Plus Drugs partners with 9amHealth on obesity care drugs
The Mark Cuban Cost Plus Drug Company has entered into a new partnership with the aim of making obesity medications...
Hims & Hers eyes $6.5B revenue target by 2030
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company’s first-quarter revenue doubled...
CMS excludes anti-obesity drug coverage under Medicare, Medicaid
The Centers for Medicare and Medicaid Services (CMS) finalized a Medicare Advantage (MA) rule proposed by the Biden administration, but...
Omada partners with CVS Caremark on weight management program
Omada Health is joining forces with CVS Health’s Caremark as part of the pharmacy benefit manager’s weight management program. This...
Biden names Ozempic, Wegovy for price negotiation program
The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the second...
New study finds 137M people are eligible for GLP-1s
Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American...
Employer family premiums rose by 7% in 2024
Family premiums in employer-sponsored coverage grew by 7% in 2024, averaging $25,572, according to a new report from KFF. This...
